Peptides / Recovery and repair

Conjugate · 343 amino acids

ACE-031 (ramatercept)

Not approvedBanned in sport

ACE-031 (ramatercept) is an engineered protein built to block signals that limit muscle growth, and its trials stopped over blood vessel safety concerns. It is not approved and is banned in sport, and small studies looked at muscle injury and repair. PepBank shows 15 results on ACE-031 from 2 studies in people, and 19 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as ACE-031, ACE031, ActRIIB-Fc, Ramatercept

First 40 of 343 amino acids3 changed amino acids

Evidence level: Some studies in people15 of 34 results come from studies in people.

Results in people

44% of 34 results

Results in animals

56% of 34 results

Results in lab cells

0% of 34 results

From computer models

0% of 34 results

Overview

ACE-031 (ramatercept) at a glance

What it is	Conjugate, 343 amino acids
Approval	Not approved for any use
In sport	Banned in sport (WADA S4.3)
Studies	6 studies with results. 4 of them gave ACE-031, with 34 results. 15 in people19 in animals
Best study in people	Randomized controlled trial (2017)
Clinical trials	4 registered: 0 active or planned, 1 with posted results
Community use	Strength

The science

What is ACE-031?

A dimeric activin receptor IIB–Fc fusion protein developed as a muscle growth ligand trap. Its clinical program stopped after vascular safety concerns.

343

Amino acids in one chain

The history of ACE-031

2008September
A registered trial of ACE-031 started (NCT00755638).
2010
The oldest paper on ACE-031 in PepBank is from 2010.

ACE-031 (ramatercept) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 343 amino acidsFrom the first amino acid to the last

G1+RG−EA5−ET+R−EC10IYYNA15NW−EL−E20+RTNQS25GL−E+RC30−EG−EQ−D35+K+RLHC40YASW+R45NSSGT50I−ELV+K55+KGCWL60−D−DFNC65Y−D+RQ−E70CVAT−E75−ENPQV80YFCCC85−EGNFC90N−E+RFT95HLP−EA100GGP−EV105TY−EPP110PTAPT115GGGTH120TCPPC125PAP−EL130LGGPS135VFLFP140P+KP+K−D145TLMIS150+RTP−EV155TCVVV160−DVSH−E165−DP−EV+K170FNWYV175−DGV−EV180HNA+KT185+KP+R−E−E190QYNST195Y+RVVS200VLTVL205HQ−DWL210NG+K−EY215+KC+KVS220N+KALP225VPI−E+K230TIS+KA235+KGQP+R240−EPQVY245TLPPS250+R−E−EMT255+KNQVS260LTCLV265+KGFYP270S−DIAV275−EW−ESN280GQP−EN285NY+KTT290PPVL−D295S−DGSF300FLYS+K305LTV−D+K310S+RWQQ315GNVFS320CSVMH325−EALHN330HYTQ+K335SLSLS340PG+K

Darker means more water-repelling+ and − show charge in the body

Structure

ACE-031 (ramatercept) is a conjugate of 343 amino acids, with no ring, 7 disulfide bonds, 3 changed amino acids.

CAS number

1169766-01-1

Target

Myostatin and other activin receptor IIB ligands: soluble receptor ligand trapEvidence: curated database or regulator description

Development

Acceleron Pharma and Shire. Highest phase: phase 2.

Identifiers

ChEMBL CHEMBL2108674, UNII 42HQC6QLEK, DrugBank DB15116

See charge, composition and 3D structure on the Scientific page

The evidence

What ACE-031 studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Some studies in people15 of 34 results come from studies in people.

Muscles and tendons

21 results · 3 in people · 18 animal

In boys with Duchenne muscular dystrophy, ACE‑031 showed a trend toward increased lean body mass. Muscle & nerve, 2017

Top results

In boys with Duchenne muscular dystrophy, ACE‑031 showed a trend toward increased lean body mass. (Muscle & nerve, 2017)
In healthy postmenopausal women, ACE‑031 increased lean body mass at day 29. (Muscle & nerve, 2013)
In healthy postmenopausal women, ACE‑031 increased thigh muscle volume at day 29. (Muscle & nerve, 2013)

Bones and joints

2 results · 2 in people

In boys with Duchenne muscular dystrophy, ACE‑031 showed a trend toward increased bone density. Muscle & nerve, 2017

Top results

In boys with Duchenne muscular dystrophy, ACE‑031 showed a trend toward increased bone density. (Muscle & nerve, 2017)
In healthy postmenopausal women, blood marker changes suggested that ACE‑031 also improved bone and fat metabolism. (Muscle & nerve, 2013)

Weight and appetite

2 results · 1 in people · 1 animal

In boys with Duchenne muscular dystrophy, ACE‑031 showed a trend toward reduced body fat. Muscle & nerve, 2017

Top results

In boys with Duchenne muscular dystrophy, ACE‑031 showed a trend toward reduced body fat. (Muscle & nerve, 2017)
In mice, ACE‑031 increased body weight compared with vehicle control. (Journal of applied physiology, 2010)

Daily life and fitness

1 result · 1 in people

In boys with Duchenne muscular dystrophy, ACE‑031 tended to preserve walking distance versus placebo, but the difference was not significant. Muscle & nerve, 2017

Top results

In boys with Duchenne muscular dystrophy, ACE‑031 tended to preserve walking distance versus placebo, but the difference was not significant. (Muscle & nerve, 2017)

All 2 studies in people

In people

In boys with Duchenne muscular dystrophy, possible widened small blood vessels contributed to stopping the ACE‑031 trial.

2017Muscle & nerve

In people

In healthy postmenopausal women, adverse events with ACE‑031 included redness at the injection site.

2013Muscle & nerve48 people

All 6 ACE-031 studies by area Open the Scientific page

Key ACE-031 studies

Studies in people come first, then studies in animals and in the lab.

People
Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial
Campbell et al. 2017 · Muscle & nerve · cited by 190
7 results
People
A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
Attie et al. 2013 · Muscle & nerve · 48 people · cited by 146
8 results
Animals
Administration of a soluble activin type IIB receptor promotes skeletal muscle growth independent of fiber type
Cadena et al. 2010 · Journal of applied physiology (Bethesda, Md. : 1985) · cited by 106
14 results
Animals
ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset (Callithrix jacchus)
Cadena et al. 2026 · PloS one · cited by 1
5 results

All 6 ACE-031 (ramatercept) studies

ACE-031 clinical trials

ClinicalTrials.gov lists 4 trials of ACE-031. 0 are active or planned, and 1 has posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Phase 2terminated24 planned

Extension Study of ACE-031 in Subjects With Duchenne Muscular Dystrophy

Phase 2terminated11 planned

A Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of ACE-031 in Healthy Postmenopausal Women

Phase 1completed70 people

1 ACE-031 (ramatercept) trial

Status and safety

Is ACE-031 approved?

FDA

United States

Not approved

No approved medicine contains it.

EMA

European Union

Not approved

No approved medicine contains it.

WADA

Sport

Banned

On the 2026 Prohibited List, section S4.3.

No. Not approved for any use. Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 21 Oct 2026). Banned in sport (WADA S4.3).

Laws and labels change, so check the regulator for the current status.

ACE-031 side effects and safety

PepBank has 5 safety results from studies of ACE-031. 5 of them come from studies in people.

Safety results from studies (5)

In boys with Duchenne muscular dystrophy, ACE‑031 was not associated with serious or severe adverse events. (Muscle & nerve, 2017)
In healthy postmenopausal women, a single ACE‑031 dose was generally well tolerated. (Muscle & nerve, 2013)
In boys with Duchenne muscular dystrophy, possible nosebleed concerns contributed to stopping the ACE‑031 trial. (Muscle & nerve, 2017)
In boys with Duchenne muscular dystrophy, possible widened small blood vessels contributed to stopping the ACE‑031 trial. (Muscle & nerve, 2017)
In healthy postmenopausal women, adverse events with ACE‑031 included redness at the injection site. (Muscle & nerve, 2013)

See every safety result on the Scientific page

Doses studied (2 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
0.02-3 mg/kg	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 48	Attie 2013
3 mg/kg	Human	human	subcutaneous	Not reported	Randomized trial in people	Attie 2013

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

One forum member reports ACE-031 use for strength. Product identity is unverified, and the clinical program stopped for vascular safety concerns.

Reported routines and cautions

What people use it for

StrengthS1

Reported regimens

Regimens that community sources report for ACE-031. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
One member report	not stated	1 mg per dose	once weekly	a few weeks	Single source. The source carries seller advertisements or affiliate links.	S1

Reported benefits (claims, not shown in trials)

Perceived strength increaseS1

Cautions

The wiki reports vascular safety concerns, including nosebleeds and telangiectasias, that stopped clinical development.S2
The wiki questions authenticity of products sold as this complex fusion protein.S2

Community sources

S1ACE-031 Dosing? EliteFitness forumwww.elitefitness.comcarries seller links, not linked
S2ACE-031 community safety contextwww.peptideprotocolwiki.comcarries seller links, not linked

Gaps

One user reports an experience. Other posts ask dosing questions or repeat trial doses. Those are not additional community regimens.

Questions and more

Ask a question about ACE-031

The answer links to every study it uses.

What does the evidence say about ACE-031?Is ACE-031 tested in people?Compare with Teriparatide (PTH 1-34)Compare with Thymosin beta-4 (human)

Sources

Database: PepBank data for ACE-031 (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about ACE-031

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

ACE-031 (ramatercept)

Not approvedBanned in sport

Also known as ACE-031, ACE031, ActRIIB-Fc, Ramatercept

What it is

Conjugate, 343 amino acids

Approval

Not approved for any use

In sport

Banned in sport (WADA S4.3)

Studies

6 studies with results. 4 of them gave ACE-031, with 34 results.
15 in people19 in animals

Best study in people

Randomized controlled trial (2017)

Clinical trials

4 registered: 0 active or planned, 1 with posted results

Community use

Strength

Dose as reported

Class

Species

Route

Duration

Design

Source

0.02-3 mg/kg

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 48

Attie 2013

3 mg/kg

Human

human

subcutaneous

Not reported

Randomized trial in people

Attie 2013

Context

Route

Amount

How often

How long

Agreement

Sources

One member report

not stated

1 mg per dose

once weekly

a few weeks

Single source. The source carries seller advertisements or affiliate links.

ACE-031 (ramatercept)

ACE-031 (ramatercept) at a glance